Sempresto has moved to strengthen its position in smartphone-integrated rescue medication technology through the acquisition of a third autoinjector platform, securing all patents and associated physical and digital assets from inventor Steven A. Friedman. The company said the newly acquired mechanisms and safety-enhancing features will support the development of next-generation, mobile-device-integrated drug delivery systems.
The acquisition further consolidates Sempresto’s position as a leading innovator in cellphone-mounted and connected drug-delivery solutions. The company expects the added intellectual property to accelerate progress on technologies that aim to improve immediate access to life-saving medications for individuals with severe allergies or other urgent medical needs.
Sempresto emphasized that the transaction broadens its foundation for creating smartphone-mounted autoinjectors that remain accessible, connected, and designed to increase patient preparedness. The company’s leadership, which includes several executives with firsthand experience managing severe allergies, continues to advance technologies aligned with its mission of ensuring that critical medications are always available when needed.
Sempresto’s flagship program features a smartphone-integrated epinephrine autoinjector intended to provide a more convenient and reliable preparedness solution for patients at risk of acute allergic reactions. The company said the acquisition of Friedman’s innovations will help propel this work and enhance the capabilities of future platforms.
KEY QUOTES:
“Friedman’s broad and innovative platform supports our strategic objectives and enhances our leadership position in cellphone-based drug delivery. By integrating his work into our expanding portfolio, we are accelerating development of technologies that will redefine how patients access life-saving medications.”
Elizabeth Reczek, PhD, CEO of Sempresto
“I am pleased that my work, with its focus on safety and portability of lifesaving medications, will be advanced by Sempresto. The leadership team—with their deep expertise and personal experience with severe allergies—are the right group to bring this vision forward and ensure it reaches the patients who need it.”
Steven A. Friedman
